Fig. 1: Flowchart of the study design and participant enrollment.
From: Efficacy and safety of Shexiang Tongxin pill for coronary slow flow in angina patients

This diagram illustrates the screening, randomization, allocation, follow-up, and analysis processes of the randomized, double-blind, placebo-controlled, multicenter trial. A total of 200 participants were enrolled and randomly assigned to either the STDP group or the placebo group. The final analysis included 199 participants who completed the study. V1, screening baseline phase (from hospital admission to the first coronary angiography) V2, medication phase 1 (sublingual medication to the second coronary angiography). Abbreviations: CTFC corrected TIMI frame count, STDP Shexiang Tongxin Dropping Pill, FAS full analysis set, PPS per protocol set, SS Safety Set.